OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
MLFMV.EUL57

Farminveste SGPS SA

Drug RetailersVerified

Farminveste SGPS SA has a liquidity position that is marginally constrained, with a current ratio of 0.95, indicating that its current liabilities slightly exceed its current assets. The company's liquidity_fpt is not explicitly provided, but the negative net cash position after subtracting total debt suggests a potential liquidity risk. The debt-to-equity ratio of 1.66 indicates a relatively high level of leverage, which could amplify financial risk in periods of economic stress. In terms of profitability, the company's return on equity (ROE) is 7.44%, which is a measure of how effectively it is using shareholders' equity to generate profits. However, the return on assets (ROA) is only 1.7%, suggesting that the company is not efficiently utilizing its total assets to generate returns. These metrics should be compared to the industry_config preferred metrics for the Drug Retailers industry to determine if the company is outperforming or underperforming its peers. The company's revenue is derived from a diverse set of segments, including pharmacies, pharmaceutical distribution, information systems, healthcare, market intelligence, real estate, and other services. The financial snapshot does not provide a breakdown of revenue by segment or geography, so it is not possible to determine the concentration of revenue in any particular area. However, the company's operations are based in Portugal, and it is likely that a significant portion of its revenue is generated domestically. The company's growth trajectory is not clearly defined in the provided data. The outlook for the current and next fiscal years is not specified, and there are no numeric deltas provided to indicate expected changes in revenue or other financial metrics. The capital expenditure of -21,488,780 EUR suggests that the company is generating more cash from operations than it is spending on capital investments, which could indicate a period of conservative investment or asset divestiture. The risk assessment indicates a medium level of liquidity risk and a low level of dilution risk. The key flag of negative net cash after subtracting total debt highlights a potential liquidity issue. The dilution potential is low, which is a positive sign for shareholders. The valuation snapshot does not provide information on adjustments applied, so it is not possible to determine if any specific factors have been considered in the valuation. Recent events, such as filings or transcripts, are not provided in the input data, so it is not possible to comment on any specific recent developments that may have impacted the company's financial position or strategic direction.

30-day price · MLFMV.EUL-0.76 (-18.3%)
Low$3.40High$4.16Close$3.40As of15 May, 00:00 UTC
Profile
CompanyFarminveste SGPS SA
TickerMLFMV.EUL
SectorConsumer Non-Cyclicals
BusinessFood & Drug Retailing
Industry groupFood & Drug Retailing
IndustryDrug Retailers
AI analysis

Business. Farminveste SGPS SA operates as a holding company in the farm industry, with business segments including pharmacies, pharmaceutical distribution, information systems, healthcare, market intelligence, real estate, and other services, generating revenue primarily through direct pharmacy services and product distribution.

Classification. Farminveste SGPS SA is classified under the Consumer Non-Cyclicals economic sector, Food & Drug Retailing business sector, and Drug Retailers industry, with a confidence level of 0.92.

Farminveste SGPS SA has a liquidity position that is marginally constrained, with a current ratio of 0.95, indicating that its current liabilities slightly exceed its current assets. The company's liquidity_fpt is not explicitly provided, but the negative net cash position after subtracting total debt suggests a potential liquidity risk. The debt-to-equity ratio of 1.66 indicates a relatively high level of leverage, which could amplify financial risk in periods of economic stress. In terms of profitability, the company's return on equity (ROE) is 7.44%, which is a measure of how effectively it is using shareholders' equity to generate profits. However, the return on assets (ROA) is only 1.7%, suggesting that the company is not efficiently utilizing its total assets to generate returns. These metrics should be compared to the industry_config preferred metrics for the Drug Retailers industry to determine if the company is outperforming or underperforming its peers. The company's revenue is derived from a diverse set of segments, including pharmacies, pharmaceutical distribution, information systems, healthcare, market intelligence, real estate, and other services. The financial snapshot does not provide a breakdown of revenue by segment or geography, so it is not possible to determine the concentration of revenue in any particular area. However, the company's operations are based in Portugal, and it is likely that a significant portion of its revenue is generated domestically. The company's growth trajectory is not clearly defined in the provided data. The outlook for the current and next fiscal years is not specified, and there are no numeric deltas provided to indicate expected changes in revenue or other financial metrics. The capital expenditure of -21,488,780 EUR suggests that the company is generating more cash from operations than it is spending on capital investments, which could indicate a period of conservative investment or asset divestiture. The risk assessment indicates a medium level of liquidity risk and a low level of dilution risk. The key flag of negative net cash after subtracting total debt highlights a potential liquidity issue. The dilution potential is low, which is a positive sign for shareholders. The valuation snapshot does not provide information on adjustments applied, so it is not possible to determine if any specific factors have been considered in the valuation. Recent events, such as filings or transcripts, are not provided in the input data, so it is not possible to comment on any specific recent developments that may have impacted the company's financial position or strategic direction.
Key takeaways
  • Farminveste SGPS SA has a high debt-to-equity ratio, indicating a leveraged capital structure.
  • The company's ROE is relatively strong at 7.44%, but its ROA is weak at 1.7%.
  • The company's liquidity position is marginally constrained, with a current ratio of 0.95.
  • The company's capital expenditure is negative, suggesting a period of conservative investment.
  • The company's risk assessment indicates a medium level of liquidity risk and a low level of dilution risk.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyEUR
Revenue$844.7M
Gross profit$97.9M
Operating income$32.7M
Net income$11.2M
R&D
SG&A
D&A
SBC
Operating cash flow$24.4M
CapEx-$21.5M
Free cash flow$2.3M
Total assets$655.8M
Total liabilities$505.7M
Total equity$150.0M
Cash & equivalents$24.0M
Long-term debt$248.5M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$150.0M
Net cash-$224.5M
Current ratio0.9
Debt/Equity1.7
ROA1.7%
ROE7.4%
Cash conversion2.2%
CapEx/Revenue-2.5%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Food & Drug Retailing · cohort 234 companies
MetricMLFMV.EULActivity
Op margin3.9%2.8% medp25 0.9% · p75 5.9%above median
Net margin1.3%1.8% medp25 0.3% · p75 3.6%below median
Gross margin11.6%24.1% medp25 13.8% · p75 31.4%bottom quartile
CapEx / revenue-2.5%-2.0% medp25 -3.8% · p75 -1.0%below median
Debt / equity166.0%56.0% medp25 14.0% · p75 113.8%top quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-04 22:39 UTC#2219f8ce
Source: analysis-pipeline (hybrid)Generated: 2026-05-04 22:41 UTCJob: 9acda190